Experts debate value of self-exam for testicular cancer

May 19, 2014 by Steven Reinberg, Healthday Reporter
Experts debate value of self-exam for testicular cancer
Researchers say study shows it saves money, but others note it doesn't appear to save lives.

(HealthDay)—Whether it's worthwhile for men to examine themselves for testicular cancer seems to depend on whom you ask.

An independent panel of U.S. experts recommends against examining your testicles for abnormalities, but a new study from University of Kansas researchers found that self-examination for testicular cancer is cost-effective.

Finding cancers early could save thousands of dollars that would be spent on treating advanced cancer, said study author Dr. Ajay Nangia, a professor of urology at the university.

However, the U.S. Preventive Services Task Force and the American Cancer Society discourage the self-exams when no symptoms are present.

According to Dr. Michael LeFevre, task force chair and a professor of medicine at the University of Missouri, the task force takes only health benefits, not costs, into account in making its recommendations.

"The task force found that there is no evidence that teaching young men how to examine themselves for testicular cancer would improve health outcomes," he said. That opinion was rendered in 2011.

Given the low prevalence of testicular cancer, limited accuracy of screening tests and no evidence for the benefits of screening, the task force concluded that the harms of screening [unnecessary treatment] exceed any potential benefits, LeFevre said.

However, he added, "the understands that many adolescent and adult males will want to continue to regularly self-examine for signs of testicular cancer and consult with their health care providers."

The findings are to be presented Saturday at the American Urological Association annual meeting, in Orlando, Fla.

When found early, testicular cancer can be treated and is usually cured. The risk of developing testicular cancer is about one in 270, while the risk of dying from it is about one in 5,000.

Dr. Otis Brawley, chief medical officer of the American Cancer Society, is concerned that focusing on testicular self-examination diverts attention from cancer prevention.

"If I give advice about testes cancer, I am diluting the advice I am giving about everything else, so I am taking away advice about diet and exercise and not smoking," he said.

"This study shows that testicular self-exams may save money, but it doesn't show that it saves lives," Brawley said.

However, men should be aware of their bodies, and if they do find a mass, they should go to the doctor, he said.

For the study, Nangia's team used Medicare reimbursements to estimate the cost to treat a missed advanced stage testicular tumor and compared that with the average cost of treating four cancerous tumors and two benign tumors found during a self- exam.

The total cost to treat so-called seminoma—slow-growing testicular cancer—was $48,877, while the total treatment cost for advanced testicular non-seminoma cancer, a more aggressive disease, was $51,592.

These costs were comparable to: 313 doctor's office visits where a benign tumor was found ($156); 180 doctor's office visits when an ultrasound was done ($272), or 79 doctor's office visits when an ultrasound and blood tests were done ($621), the researchers said.

Looked at another way, treating those same advanced cancers could pay for six doctor's office visits resulting in removal of the testicles for benign tumors ($7,686) or three office visits resulting in detection, treatment and surveillance of an early-stage testicular cancer ($19,438 seminoma; $26,190 non-seminoma), the study found.

Nangia cited a 3:1 cost-benefit ratio for identifying testicular cancer early versus detecting it in an advanced stage.

Based on this finding, the researchers concluded that testicular self-examination is cost-effective and should be promoted.

Another presentation at the meeting found racial disparities in diagnosis of testicular cancer and survival rates.

Data on nearly 76,000 men from the National Cancer Data Base found that almost 16 percent of blacks with testicular cancer were diagnosed when the cancer was advanced, compared with about 14 percent of Asian men and 11 percent of whites.

Hispanics, however, had the highest rate of advanced testicular cancer when diagnosed—about 17 percent, the researchers said.

Moreover, blacks were twice as likely to die from as whites with similar stage at diagnosis.

Data and conclusions presented at meetings are typically considered preliminary until published in a peer-reviewed medical journal.

Explore further: Testicular cancer on rise in US, especially among Hispanic men

More information: For more information on testicular cancer, visit the American Cancer Society.

Related Stories

Testicular cancer on rise in US, especially among Hispanic men

May 3, 2013
(HealthDay)—The number of testicular cancer cases continues to climb slowly but steadily in the United States, according to new research.

Nearly all men survive testicular cancer

July 29, 2013
Survival for testicular cancer has risen by almost 30 per cent in the last 40 years, with nearly all men now beating the disease, according to figures published by Cancer Research UK.

Marijuana use may increase risk of testicular cancer: study

September 10, 2012
A new study from the University of Southern California (USC) has found a link between recreational marijuana use and an increased risk of developing subtypes of testicular cancer that tend to carry a somewhat worse prognosis. ...

Primary health risks outweigh long-term radiation concerns

March 15, 2013
(HealthDay)—Immediate health risks supersede lifetime radiation-induced cancer risk in patients undergoing computed tomography (CT) surveillance for testicular cancer, according to a study published in the March issue of ...

Chemotherapy before radiotherapy for testicular cancer could reduce long-term side-effects

August 16, 2013
Giving men with testicular cancer a single dose of chemotherapy alongside radiotherapy could improve the effectiveness of treatment and reduce the risk of long-term side-effects, a new study reports. As many as 96% of men ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.